ANDA 90926, held by Glenmark Pharmaceuticals. Montelukast Sodium.
As of Nov 21, 2026, ANDA 90926 (Montelukast Sodium), held by Glenmark Pharmaceuticals, was first approved by FDA on Aug 3, 2012, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Montelukast SodiumEQ 10MG BASE · tablet;oral | Montelukast Sodium | Rx |
| May 10, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 10, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 7, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 7, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 7, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 7, 2019 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 3, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters